RT-102
Peptide
Evidence outlook · program status
Discontinued, as a strategic decision by the sponsor
Rani's FY2025 10-K: in 2026, as part of a strategic prioritization of its pipeline, Rani discontinued RT-102 (osteoporosis) and RT-110. Rani keeps the rights, may explore partnerships, and has no current plans to resume development. No exact date is stated. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Review complete: no registered study met the criteria for featured evidence in this indication.
No registered study of RT-102 enrolled patients with osteoporosis; its only registered study (NCT05164614) was in healthy volunteers, and Rani discontinued the program in 2026.
0 registry matches · 0 candidates
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1 (1)
What this study did
Competitive landscape
This drug's own stage for Osteoporosis: Discontinued. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| RT-102: this drug | Discontinued | Peptide | PTH1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Denosumab (Prolia) | Approved | Monoclonal antibody | RANKL | not yet graded | No reviewed efficacy summary in this indication | |
| Zoledronic Acid (Reclast) | Approved | Small molecule | Farnesyl pyrophosphate synthase (FPPS) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.